HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PharmaTech Adds Supplements To Recall Nearly A Month After Drugs

This article was originally published in The Rose Sheet

Executive Summary

In addition to Major and Rugby supplement brands marketed by Cardinal Health subsidiary Harvard Health Group, PharmaTech's recall includes products it makes for the BProtected, Renew HC and Cytodetox brands.

You may also be interested in...



PharmaTech’s Water Problem Reaches OTCs In Ninjacof Recall

Ninjacof cough and cold products are recalled by Richland, MS-based marketer Centurion Labs as a precaution after FDA warns the firm of risk for contamination by burkholderia cepacia, a pathogen that can cause infections in patients with compromised immune systems.

PharmaTech’s Water Problem Reaches OTCs In Ninjacof Recall

Ninjacof cough and cold products are recalled by Richland, MS-based marketer Centurion Labs as a precaution after FDA warns the firm of risk for contamination by burkholderia cepacia, a pathogen that can cause infections in patients with compromised immune systems.

PharmaTech Recalls Highlight Supplement GMP Diligence For Marketers – CRN

PharmaTech customers recall liquid supplements, including products indicated for children, after CDC informs FDA that an antibiotic-resistant pathogen was found in a PharmaTech Rx drug. CRN says the recall should remind supplement firms about tracking supply chains and auditing contract manufacturers.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS108497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel